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WS12.1 The prevalence of substance abuse in cystic ﬁbrosis
S. Malhotra1, N. Brager1, H.R. Rabin1, M.D. Parkins1, M. Hertzsprung1,
J. Leong1. 1University of Calgary, Calgary, Canada
Background: Substance abuse is very prevalent in today’s society and has numerous
consequences on the physical and psychological health of individuals. Little is
known about the prevalence of substance abuse in patients with chronic diseases.
Cystic ﬁbrosis is the most common lethal genetic disease in Caucasian populations.
Previous research on substance abuse in patients with CF is limited. Given the
serious nature of the illness and the multiple body systems involved, understanding
more about substance abuse in CF could have signiﬁcant implications for the health
and treatment of these patients.
Objectives: The purpose of our study was to determine the prevalence of substance
abuse in cystic ﬁbrosis patients.
Methods: Participants were recruited from the Calgary Adult Cystic Fibrosis
Clinic and informed consent was obtained. Participants completed a demographics
questionnaire, the AUDIT (alcohol use disorders identiﬁcation test) and the DAST
(drug abuse screening test).
Results/conclusions: A total of 100 participants (57 females, 43 males) with CF
completed the study. The average age of participants was 28.9. The prevalence of
alcohol abuse was 16% and the prevalence of drug abuse was 4%. In our study
82% of participants drank alcohol in the past year, 20% used drugs in the past
year and 5% smoked cigarettes regularly. 1% of participants admitted overusing
pain medications. Only 3.2% of the sample had addiction treatment in the past.
Information gathered from this study could be used to inform and encourage
clinicians to ask about substance use in this population. This could lead to earlier
detection and treatment for these patients which may improve outcomes.
WS12.2 Outcomes of patients with cystic ﬁbrosis admitted to an
intensive care unit
B. Markewitz1, D. Markewitz1, R. Liou1, T.G. Liou1,2. 1University of Utah Health
Sciences Center, Salt Lake City, United States; 2Intermountain Cystic Fibrosis
Center, Salt Lake City, United States
Objective: Describe the indications for care and outcomes of cystic ﬁbrosis (CF)
patients admitted to an intensive care unit.
Methods: Retrospective chart review.
Results: Between 2005 and 2009 18 patients had 20 admissions to the medical
intensive care unit (ICU) service at the University of Utah Hospital. The reasons for
admission were hemoptysis 5 (25%), CF exacerbation/respiratory failure 13 (65%),
pneumothorax 1 (5%), and medication overdose 1 (5%). Assisted ventilation was
required in 13 (65%) patients. This was in the form of non-invasive ventilation
(NIV) in 11 (55%) and intubation and mechanical ventilation in 7 (35%). Four
of the patients receiving NIV went on to intubation. The median ICU length of
stay was 1.5 days with a range of 1 to 55 days. ICU and hospital survival were
75% and 70% respectively. Ninety day and one-year survival were 68% and 63%
respectively with one patient lost to follow up. Causes of respiratory failure resulting
in intubation were hemoptysis (2, both survived), medication overdose (1, survived),
and CF exacerbation (4, 1 survivor who was transplanted). All patients admitted with
hemoptysis were alive one year after the ICU admission. Of the patients admitted
with a CF exacerbation/respiratory failure one-year survival was 50% with one
patient lost to follow up.
Conclusions: The majority of CF patients requiring intensive care described here
had a brief ICU stay. The majorities of patients survived the ICU admission,
hospitalization, and were alive at one-year follow-up.
WS12.3 Educational needs for transplanted cystic ﬁbrosis patients
V. David1, C. Berville1, S. Ravilly2, C. Marchand3. 1CHU Nantes, Nantes, France;
2Vaincre la Mucoviscidose, Paris, France; 3University Paris 13, Health Education
Laboratory, Bobigny, France
Introduction: After lung transplantation, cystic ﬁbrosis patients have a lot of new
skills to acquire: new medications, risks of new emergency situations, rejections,
and infections.
Objectives: This study is to clarify the needs in therapeutic education for these
patients. Since 2009, 43 adult patients, followed in 6 French transplant centres,
have been enrolled and have realised an interview called “educational diagnosis”.
Methods: Educational diagnosis has four parts:
– general initial interview that explores several dimensions: biomedical, socio-
professional and cognitive
– visual evaluation of quality of life on analogical scale
– several questions about the role of medications and a self-measure of adhesion
to these treatments
– knowledge questionnaire.
Results: This exhaustive interview shows that most of patients would like to meet
more often social workers to help them manage time at work. Needs in psychologists
treatments are also commonly identiﬁed. Most patients have excellent adherence to
immunosuppressive therapy but do not regularly take the other medications: for
example, pancreatic enzymes, vitamins, inhaled treatments. They forgot the roles
of these drugs. Difﬁculties in adapting to some situations have been remarked as
“what I must do if I forget my immunosuppressive treatment” or “if I vomit”.
Diabetic patients need speciﬁc educational sessions.
Conclusion: To answer questions identiﬁed by the “educational diagnosis”, we have
developed pedagogic tools that are proposed to these patients. The study is on going
to assess interest of educational sessions with these tools.
This study is supported by Vaincre la Mucoviscidose.
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Objectives: Infection control policies recommend segregation of people with CF
according to bacterial status. This involves isolating those with cepacia from
all others in order to prevent cross infection. Service user reports suggest that
emotions like anxiety and anger are aroused when those with cepacia are faced
with cross infection measures (UK CF Trust, 2009). No studies to date investigate
this anecdotal emotional reaction.
Methods and Results: This research was conducted to ask what it is like to live
with cepacia, using in depth interviews. A phenomenological approach was used.
Three themes appeared to characterise the experience of living with cepacia:
1. Lost identity − Cepacia can challenge one’s self identity, and along with cross
infection measures lead to feeling objectiﬁed and even alienated from the
CF group identity.
2. Status: Condemned − Being colonised with cepacia brings with it knowledge of
a restricted future and an imagined death. There is loss of normality and hope.
3. I am cepacia − Decisions about preventing cross infection is inﬂuenced by
medical knowledge as well as human emotions and social information; therefore
adherence to these measures is ﬂuid and contextual.
Conclusions: These themes have real world clinical implications for all CF services,
where preventing the spread of cepacia is paramount. Responsibility for cross
infection is a burden and requires understanding from both those living with and
without cepacia − we need to see beyond the bacteria to the person.
